Tristel plc (AIM:TSTL)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 196.52M +23.0% |
| Revenue (ttm) | 49.54M +13.7% |
| Net Income | 7.86M +28.1% |
| EPS | 0.16 +26.1% |
| Shares Out | 47.93M |
| PE Ratio | 25.25 |
| Forward PE | 23.67 |
| Dividend | 0.14 (3.46%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 34,833 |
| Average Volume | 94,077 |
| Open | 420.00 |
| Previous Close | 410.00 |
| Day's Range | 400.00 - 420.00 |
| 52-Week Range | 340.00 - 445.00 |
| Beta | 0.34 |
| RSI | 66.14 |
| Earnings Date | Jun 1, 2026 |
About Tristel
Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers device decontamination products, including wipes system, ULT, OPH, Stella system, fuse for Stella, rinse assure, clean, EVE, medistel, EVA system, daisygrip, fuse for surfaces, dosing system, airstel, enzystel, DOK, pre-clean wipes, rinse wip... [Read more]
Financial Performance
In fiscal year 2025, Tristel's revenue was 46.46 million, an increase of 10.80% compared to the previous year's 41.93 million. Earnings were 6.64 million, an increase of 2.33%.
Financial StatementsNews
Half Year 2026 Tristel PLC Live Online Presentation Transcript
Half Year 2026 Tristel PLC Live Online Presentation Transcript
Tristel Earnings Call Transcript: H1 2026
Record interim revenue and profit growth driven by strong UK, European, and U.S. performance, with robust cash generation and continued investment in commercial expansion. U.S. market momentum accelerates, supported by clinical guideline endorsements and strategic partnerships.
Full Year 2025 Tristel PLC Online Investor presentation Transcript
Full Year 2025 Tristel PLC Online Investor presentation Transcript
Tristel Earnings Call Transcript: H2 2025
Double-digit revenue and profit growth were achieved, with strong margins and a 5% dividend increase. U.S. expansion, new product launches, and manufacturing efficiencies support a positive outlook, with double-digit growth targeted through 2030.
Tristel Transcript: CMD 2025
Strong financial growth continues, driven by geographic expansion, U.S. market entry, and product innovation. Focus remains on high-margin infection prevention niches, digital transformation, and leveraging customer advocacy for further penetration.
Half Year 2025 Tristel PLC In-person Presentation Transcript
Half Year 2025 Tristel PLC In-person Presentation Transcript
Tristel revenue up as it targets opportunities in high-growth markets
Tristel sees strong performance as it continues to focus on opening up new high-growth overseas markets under new CEO Matt Sassone
Tristel Earnings Call Transcript: H1 2025
Revenue grew 8% to £22.6m and adjusted profit before tax rose 19% to £4.9m, with strong cash generation and no debt. Growth is driven by medical device decontamination, with the US market and new product launches providing significant future opportunities.
Full Year 2024 Tristel PLC Analyst briefing Transcript
Full Year 2024 Tristel PLC Analyst briefing Transcript